Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6.

"Disclosures Dr Strain has received speaker honoraria, conference sponsorship, and unrestricted educational grants from, and/or attended meetings sponsored by, AstraZeneca, Bayer, Eli Lilly, Janssen, Merck, Napp, Novartis, Novo Nordisk, Sanofi Aventis, and Takeda. Dr Strain is supported by the National Institute for Health and Care Research (NIHR) Exeter Clinical Research Facility. The views expressed in this publication are those of the authors and not necessarily those of the NIHR Exeter Clinical Research Facility, the NHS, the NIHR or the Department of Health in England. Dr Frenkel is a Novo Nordisk employee and stockholder. Previous employment at Roche Pharmaceuticals. Dr James has received honoraria and support for conference expenses from Daiichi-Sankyo, Amgen, Portola, and Medtronic. Dr Leiter has received honoraria for advisory board participation from, and has provided continuing medical education on behalf of, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, Pfizer, Sanofi, and Servier; and has received research grants from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Lexicon, Novo Nordisk, and Sanofi. Dr Rasmussen is a Novo Nordisk employee and stockholder. Dr Rothwell has received honoraria for advisory board or trial committee participation from Abbott, Bayer, and Bristol Myers Squibb. Dr Ripa is a Novo Nordisk employee and stockholder. Dr Truelsen has received honoraria for advisory board participation from Boehringer Ingelheim, Medtronic, and Novo Nordisk; speaker honoraria from Boehringer Ingelheim, Medtronic, Bristol Myers Squibb, and AstraZeneca; research grants from Novo Nordisk Foundation; and consultancy fees from Janssen Biotech. Dr Husain has received personal fees from Boehringer Ingelheim and Janssen Inc. for advisory panel consultancy and speaker honoraria; grants and personal fees from AstraZeneca and Merck & Co for advisory panel consultancy and investigator-initiated clinical and preclinical research; personal fees from Roche for advisory panel consultancy; and grants and personal fees from Novo Nordisk for advisory panel consultancy, speaker honoraria, and investigator-initiated preclinical research. Provisional patent for methods for inhibiting platelet aggregation using GLP-1 (glucagon-like peptide-1) receptor agonists, patent No. US61/721,819; patent issued for peptides and methods for preventing ischemic tissue injury, patent No. US61/719,075."

"Sources of Funding This study was funded by Novo Nordisk A/S (Søborg, Denmark). Writing and editorial assistance was provided by Jin Heppell, PhD, and Izabel James‚ MBBS‚ of Ashfield MedComms, funded by Novo Nordisk A/S (Søborg, Denmark)."

"Registration:: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01720446 and NCT02692716."